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Abstract
Urinary tract infection is one of the most common bacterial infections worldwide. Current
diagnosis of urinary tract infection chiefly relies on its clinical presentation, urine dipstick
tests and urine culture. Small molecules found in bio-fluids related with both infection and
recovery would facilitate diagnosis and management of UTI. Mass spectrometry-based fin-
gerprinting of plasma and urine at 3 time points, pre-infection (t = -24h), infection (t = 24h)
and post 3-day treatment (t = 112h), were acquired in the following four groups: mice which
were healthy, infected but not treated, infected and treated with ciprofloxacin, and infected
and treated with Relinqing® granules (n = 6 per group). A metabolomics workflow including
multivariate analysis and ROC regression was employed to select metabolic features that
correlated with UTI and its treatment. Circa 4,000 molecular features were acquired for each
sample. The small acid 3-hydroxybutyrate in plasma was found to be differentiated for uri-
nary tract infection, with an area under the curve = 0.97 (95% confidence interval: 0.93–
1.00, accuracy = 0.91, sensitivity = 0.92 and specificity = 0.91). The level of 3-hydroxybuty-
rate in plasma was depleted after infection with a fold change of -22 (q < 0.0001). Correlation
between plasma 3-hydroxybutyrate and urine bacterial number in all groups and time points
was r = -0.753 (p < 0.0001). The findings show that 3-hydroxybutyrate is depleted in blood
and strongly associated with UTI at both infection and post-treatment stage in a UTI mouse
model. Further work is envisaged to assess the clinical potential of blood tests to assist with
UTI management.
Introduction
Urinary tract infection (UTI) is one of the most common bacterial infectious diseases,
including a variety of clinical symptoms that range from mild to life-threatening [1, 2]. It is
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estimated that the incidence of UTI causes near 8 million ambulatory care visits and 1.7 mil-
lion visits to emergency departments annually in USA. In the UK it accounts for 22% of
emergency admissions [3]. UTI affects all age groups with females being at higher risk. As
many as 50% females will suffer from urinary tract infections in their life and nearly 25% of
them will develop recurrent urinary tract infections [4–6]. UTI often results from both
Gram-positive and Gram-negative bacteria, but it can also occur due to a virus or fungus [1,
7]. The most common pathogen is Escherichia coli (E.coli) which accounts for 80–85% of uri-
nary tract infections [8].
To treat UTI is challenging, not only because of the high prevalence and potential mor-
bidity of UTI, but also because of its relatively complicated diagnosis and the prevailing
emergence of multidrug-resistant pathogens [1, 9]. Misdiagnosis can cause unnecessary or
inappropriate antibiotic treatment which can then result in antibiotic resistance [10].
Delayed diagnosis can lead to failure of appropriate treatment which might cause long-term
morbidity, kidney scarring, hypertension and renal damage [11]. Urine culture is regarded
as the gold standard for the diagnosis of UTI. The detection of a positive culture result
requires at least 18 hours, which can lead to a delayed treatment [11]. Moreover, there is a
risk of urine contamination and there is no agreement on the diagnostic cut-off [10, 12].
Clinical presentation poses a great challenge for diagnosis in babies and older people or
immunocompromised individuals as it is usually non-specific [13]. Dipstick tests are com-
monly used in daily practice; however, these tests can have low sensitivity and specificity,
hence lacking accuracy [14]. Therefore, a complementary diagnosis in bio-fluid that reflects
the host’s response to pathogens in the urinary tract would be valuable for better manage-
ment of UTI [2].
Discovery studies aim to find markers or indicators that can be objectively measured and
used to diagnose the presence or progress of disease [15]. To this end “-omic” technologies
provide a hypothesis free platform for the discovery of individual and panels of molecules that
associate with clinical outcomes [16]. Metabolomics also called metabolic phenotyping focuses
on analysing small metabolites (molecular weight <1 kDa) present in bio-fluids [17]. These
metabolites are not only the end products of the pathways of a living system, but also the
results of the interaction between genes and the environment [2].
Previous work concerning UTI biomarker discovery focused on metabolites and pro-
teins. Lam CW., et al. analysed 88 patients’ urine and reported urine acetic acid alone as a
promising UTI biomarker with 1H NMR spectroscopy. After this they discovered trimethy-
lamine in urine to correlate with E.coli-associated UTI with an area under the curve of 0.85
and sensitivity of 0.67 [18, 19]. Yim et al suggested that urine neutrophil gelatinase-associ-
ated lipocalin (uNGAL), kidney injury molecule-1 (uKIM-1) levels might be useful markers
for febrile UTI in children (n = 73 pediatric patients) [20]. Leroy et al. conducted a system-
atic review, involving 18 studies and 1101 patients, and recommended procalcitonin, a pro-
peptide of calcitonin, to be a good predictor to differentiate acute pyelonephritis and lower
UTI in children [21]. A summary of studies on UTI biomarker discovery is provided in
Table 1.
The main purpose of this study is to scan for metabolites associated to a UTI model, to
study the systemic effect caused by bacteria and ideally to be able to monitor the recovery pro-
cess. With this model, we investigated both plasma and urine longitudinal metabolic finger-
prints from a pre-infection to a post-treatment stage. Infected mice were sub-grouped and
given different treatments, namely saline, ciprofloxacin, and Relinqing1 granules. Relinqing1
granules are an SFDA approved drug based solely on Polygonum capitatum Buch.-Ham.exD.
Don, a herbal medicine long used in south-western China for the treatment of urinary tract
infection [22].
Plasma 3-hydroxybutyrate and infection
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Table 1. Summary of UTI biomarker studies.
Model Sample Changed Metabolite AUC, Sensitivity, Specificity Ref.
Human Urine "trimethylamine (TMA) TMA/creatinine
AUC = 0.97,
sensitivity = 0.91
specificity = 0.95
[18]
Human Urine "acetic acid Acetic acid/creatinine
AUC = 0.97,
sensitivity = 0.91
specificity = 0.95
[19]
Human Urine, " neutrophil gelatinase-associated lipocalin (NGAL),
" kidney injury molecule-1(KIM-1)
NGAL/creatinine
AUC = 0.90,
sensitivity = 0.76
specificity = 0.90
KIM-1/creatinine
AUC = 0.66,
sensitivity = 0.45
specificity = 0.82
[20]
Rat Urine "neutrophil gelatinase-associated lipocalin (NGAL) n/a [23]
Dog Urine "neutrophil gelatinase-associated lipocalin (NGAL) sensitivity = 0.76
specificity = 0.69
[24]
Human Urine "endothelin-1 (ET-1) n/a [25]
Human with UTI recurrence Urine #urinary nerve growth factor (uNGF) n/a [26]
Human Urine "neutrophil gelatinase–associated lipocalin (NGAL) AUC = 0.97,
sensitivity = 0.98
specificity = 1.00
[27]
Rat Urine "neutrophil gelatinase-associated lipocalin (NGAL),
" kidney injury molecule-1(KIM-1)
NGAL/creatinine (2 days after infection)
AUC = 1.00,
sensitivity = 1.00
specificity = 1.00
NGAL/creatinine (7 days after infection)
AUC = 0.87
sensitivity = 0.80
specificity = 0.80
KIM-1/creatinine (2 days after infection)
AUC = 0.87
sensitivity = 0.80
specificity = 0.80
[28]
Human Serum "procalcitonin n/a(meta-analysis) [21]
Human Plasma " soluble urokinase plasminogen activator receptor (suPAR), n/a [29]
Human Urine "heparin-binding protein (HBP) AUC = 0.95,
sensitivity = 0.89
specificity = 0.90
[30]
Human Urine "xanthine oxidase (XO)
"myeloperoxidase
(MPO)
XO
sensitivity = 1.00
specificity = 1.00
MPO
sensitivity = 0.87
specificity = 1.00
[31]
Human Urine "human α-defensin 5 (HD5)
"human neutrophil peptides (HNP) 1–3
HD5
AUC = 0.86,
sensitivity = 1.00
specificity = 0.65
HNP1-3
AUC = 0.88
sensitivity = 0.97
specificity = 0.65
[32]
https://doi.org/10.1371/journal.pone.0186497.t001
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Materials and methods
Samples and reagents
Bacterial strains and culture medium. Escherichia coli ATCC25922 bacteria were pur-
chased from the National Centre for Medical Culture Collection (China), Mueller-Hinton
Agar culture medium (batch number: 20140924–00), Nutrient Agar culture medium (batch
number: 20140304–01) were purchased from Hangzhou Microbial Regent Co., Ltd (China).
Chemical reagents. LC-MS grade water, LC-MS grade acetonitrile were purchased from
VWR international (UK). LC-MS grade methanol, N,O-bis(trimethylsilyl)trifluoro-acetamide
(BSTFA) with 1% trimethylchlorosilane (TMCS), O-methoxyamine-HCL (MOX), succinic-d4
acid were purchased from Sigma-Aldrich (UK). Ciprofloxacin (batch number: 1130026) was
purchased from Guangzhou Bai Yun Shan Pharmaceutical General Factory (China). Relinq-
ing1 granules (batch number: 141005) was purchased from Guizhou Wei Men Pharmaceuti-
cal Company.
Methods
UTI mouse model built and evaluation. Preparation of bacterial solution: E. Coli
ATCC25922 was incubated in Mueller-Hinton Agar broth for 24h with shaking at a tempera-
ture of 37˚C. Turbidimetric tube was used to compare the concentration of culture. Then the
E. coli culture was diluted to appropriate concentration with sterile physiological saline to
establish urinary tract infection mouse model.
Study of inoculated E.coli suspension concentration: Twenty-four mice were randomly
divided into four groups. After anaesthesia with 10% chloral hydrate, the mouse bladder was
voided by gentle squeeze of the abdomen. Then the mice in different groups were inoculated
with different concentration of E. coli suspension (1×107、1×108、1×109 and 5×109 cfu/mL).
The inoculation volume was 0.05mL. After inoculation, the mice were deprived of water for 4h
to ensure the complete interaction of the E.coli adhesion with cellular receptors in the bladder.
Then they were back to normal water and food consumption. The early morning urine was
collected 24h later and diluted by 10-fold (10−1, 10−2, 10−3 respectively). 0.5mL of urine was
taken for urine culture. Pouring plate method was used to culture diluted urine and the urine
samples were placed in 37˚C incubator for culture.
Study of inoculated E.coli suspension volume: A similar procedure was applied. Twenty-
four mice were randomly divided into four groups and received the same operation as men-
tioned above. One group was used as the blank control, while the other three groups received
different volume of E.coli suspension (0.05、0.1、0.15 mL) at the concentration of 1×107
cfu/mL. 5 min later, orbital blood was collected and the blood samples were centrifuged at
15000rpm for 5min. The plasma obtained was diluted by 10 times (10−1, 10−2, 10−3 respec-
tively). 0.5mL of serum samples was taken and pouring plate method was applied for serum
culture and then bacterial number was counted.
Another eighteen mice were randomly divided into three groups. The mice in different
groups were inoculated with different volume of E. coli solution (0.05、0.1、0.15 mL) at
the concentration of 1×107 cfu/mL. Same method was applied to collect and culture urine
sample.
UTI model built [33]: Animal studies were approved by the Experiment Animal Centre of
Guizhou Medical University and carried out in strict accordance with the guidelines of the
National Institutes of Health for the Care and Use of Animals in China. Specific-pathogen-free
(SPF) KM female mice (20±2g, 7–8 weeks) (certificate no. SCXK 2014–0011) were purchased
from Changsha Tianqin Biotechnology Co., Ltd (China). Before the experiments, the mice
Plasma 3-hydroxybutyrate and infection
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were allowed one week of acclimatization in the animal quarters under air conditioning (22
±2˚C) with relative humidity of 50–60%.
Animals were anesthetized with 10% chloral hydrate. Prior to the establishment of the
model, the mouse bladder was gently squeezed to empty the urine. During infection, 0.05mL
of E. coli suspension delivering 1×109 cfu/mL was instilled into bladder through a polypropyl-
ene tube (inner diameter 0.28mm, outer diameter 0.61mm; Smith Medical Company, UK)
over a period of 30s [34]. After inoculation, the mice were deprived of water for 4h and then
were back to normal water and food consumption. Healthy control mice (mock-infection)
were injected with sterile saline (without E. coli) into the bladder.
The urine samples collected in the morning before and after the infection were used to
assess the sterility and the model. All urine samples were diluted by 10 times, 100 times and
1000 times respectively. 0.5mL of diluted urine was used for urine culture. Urine was incu-
bated at 37˚C incubator and the number of bacteria number was counted after 24h.
Group information and sample collection. 6 mock-infected mice were used as control
group (CTR). 18 successfully infected mice were randomly divided into three groups (n = 6
per group), the UTI group (UTI): treated with saline; the ciprofloxacin group (CPF): treated
with ciprofloxacin and the Relinqing1 granules group (RLQ): treated with Relinqing1 gran-
ules. Two infection treatments were included to ascertain the association of selected features
with bacterial count independently of the mode of action of a specific treatment.
Both UTI and CTR groups were administered saline twice a day for three days. CPF and
RLQ group were dosed with ciprofloxacin or Relinqing1 granules by oral gavage at 0.081g/kg
and 1.73g/kg respectively twice a day for three days. In the plasma and urine multivariate and
univariate analysis, UTI, CPF, and RLQ groups were assigned as Infected Group.
Both plasma and 24h-urine samples were collected 24h before infection (time point 1) and
24h after infection (time point 2). Immediately after the collection of time point 2 samples, ani-
mals started three-day treatment. 16h after three-day treatment, plasma and urine samples
were collected again (time point 3). All the plasma and urine samples (100μL of plasma and
20 μL of urine) were lyophilized and stored in -80˚C until use. A figure describing the experi-
mental design can be seen in Fig 1. Table 2 shows the urine bacterial number of mice at differ-
ent time points.
Sample preparation for metabolomics analysis. Lyophilized mouse plasma and urine
was reconstituted in 100μL/ 20μL of water and vortexed for 2min. Then 300μL/ 60μL of metha-
nol with 20μg/mL of succinic-d4 acid as internal standard added for protein precipitation.
Samples were centrifuged for 10 mins at 10,000g at 4˚C. 100μL/20μL of supernatant was trans-
ferred to a new vial. A pooled sample from all the plasma or urine samples was used as a quality
control (QC).
All the samples were dried under N2. Then the residue of plasma/urine was added with
50μL/ 20μL of MOX in pyridine (20mg/mL) and heated for 30min at 70˚C. Samples were
dried down and 100μL/ 30μL of BSTFA (1% TCMS) and 30μL of acetonitrile were added for
silylation. The silylation procedure was carried out by incubating the samples at 70˚C for 1h.
Then samples were pipetted to amber HPLC vials with inserts.
Metabolomics analysis was performed on a Shimadzu GC-2010 Plus gas chromatography
system coupled to a GCMS-QP2010 SE single quadruple mass spectrometer (Shimadzu,
Kyoto, Japan). Samples were separated on a 30m×0.25mm×0.25μm, BP5MS capillary col-
umn. The initial oven temperature was maintained at 60˚C for 1 minute, and then raised to
320˚C at a rate of 10˚C/min, holding for 4minutes. Helium was used as the carrier gas at a
flow rate of 40cm/sec. The temperatures for injection, ion source and interface were set at
280˚C, 200˚C and 320˚C respectively. The injection volume was 0.5μL in the split mode with
the split ratio of 1:60. Solvent cut time was 5 minutes. Mass data were collected in SCAN
Plasma 3-hydroxybutyrate and infection
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mode (m/z 50-600Da) with an event time 0.2s. Electron impact ionization energy was kept at
70eV.
Data pre-processing. All GC-MS raw data were converted to mzXML format by the
GCMS Postrun Analysis file converting utility (Shimadzu, Kyoto, Japan). The converted data
files were then processed using the free “R” package “XCMS” for peak picking and retention
time correction. Identification was performed by comparing fragmentation patterns of
detected metabolites with the spectra in National Institute of Standards and Technology
(NIST) and Shimadzu libraries and then confirmed with the pure standard compound.
Statistical analysis. Statistical modelling was accomplished in SIMCA version 14 (MKS
Umetrics AB, Sweden). Data were subjected to data modelling, including orthogonal partial
least squares-discriminant analysis (OPLS-DA) with corresponding S-plot to mine relevant
features. Data were both log-transformed and Pareto-scaled. Selection of discriminating
Fig 1. Experimental design for UTI metabolomics study.
https://doi.org/10.1371/journal.pone.0186497.g001
Table 2. Bacterial number in mice urine (cfu/mL).
CTR Group
(n = 6)
UTI Group
(n = 6)
CPF Group
(n = 6)
RLQ Group
(n = 6)
Pre-infection
(T1)
0 0 0 0
Infection
(T2)
0 (2.87±0.51)×105 ***a (2.72±0.44)×105 ***a (3.24±0.79)×105 ***a
Post-treatment
(T3)
0***b (2.00±0.69) ×105 0***b (0.26±0.53) ×105 **b
Data are expressed as means ± S.D.
cfu: colony forming unit
a. Comparison between CTR and UTI/ CPF/RLQ groups at time point 2 showing the mice were successfully infected, Mann-Whitney test, *** p <0.001
b. Comparison between UTI and CTR/CPF/RLQ groups at time point 3 showing the treatments were effective, Mann-Whitney test,
*** p <0.001,
** p< 0.01
https://doi.org/10.1371/journal.pone.0186497.t002
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features were based on covariance p[1] and correlation p(corr) values in the S-pot (p[1]>0.10,
p(corr)>0.60 and p[1]<-0.05, p(corr)<-0.80). Selected features were measured again in the
raw data (area under the peak) and univariate analysis was performed. The receiver operating
characteristic (ROC) curve was used to assess the prediction ability of the selected features. All
statistical tests including t-test, Mann-Whitney test, Spearman correlation, and Wilcoxon
signed ranks test were performed in SPSS (IBM SPSS statistics, version 22). P values were
adjusted to multiple testing with Benjamini and Hochberg correction when necessary and
reported as q-values. A ROC curve was built in “R” with “pROC” package (with a threshold of
0.5). The data treatment workflow for metabolomics discovery is demonstrated in S1 Fig.
Results
UTI mouse model built and evaluation
Optimization of inoculum concentration and volume. The inoculation concentration
and volume of E.coli suspension were studied. It could be observed that with the increase of
concentration, the urine bacterial number was also elevated. However, when the concentration
reached 5×109 cfu/mL, the increase of bacterial number was not significant. The results are
shown in S1 Table.
Inoculum volume experiments showed a similar pattern where the urine bacterial number
increased moderately with the increase of inoculation volume (results shown in S2 Table).
Moreover, at inoculum volume of 0.05 ml, plasma cultures of all tested mice were sterile, but
when the inoculation volumes were bigger (0.1mL and 0.15mL), plasma cultures of three mice
(one with 0.1mL, two with 0.15mL) were positive indicating bacteraemia. Therefore, 0.05mL
with concentration of 1×109 cfu/mL was chosen for the UTI mouse model, conditions that
were in accordance with Lane et al [34].
UTI model evaluation. Urine culture was used to assess the status of bacterial growth at
different time points. At pre-infection stage (T1), no bacterial colony was observed in the cul-
ture medium. At infection stage (T2), the urine culture results were positive for the mice
infected with E.coli. The bacterial numbers can be seen in Table 2.
Plasma creatinine, a biomarker used routinely for kidney function, was also measured
before and after infection [35]. Result showed that there was no difference between T1 and T2
indicating no changes in renal function (data not shown).
Plasma untargeted multivariate analysis
Infected group plasma multivariate analysis between T1 and T2. OPLS-DA model cre-
ated from GC-MS plasma data revealed a significant variation between pre-infection (T1) and
infection (T2) in terms of metabolic profiles (Fig 2A). With this model, four metabolites differ-
entiated pre-infection and infection with p[1]>0.10, p(corr)>0.60 and p[1]<-0.05, p(corr)<-
0.80 were selected by the corresponding S-plot (Fig 2B). These four metabolites were identified
as lactate, urea, cholesterol and 3-hydroxybutyrate (3-HB).
Univariate analysis of selected features. Metabolite semi-quantification: The peak areas
of four metabolites were measured in the raw data (normalized to internal standard) for uni-
variate analysis. Lactate and cholesterol were excluded after univariate analysis as differences
in the raw data were not significant.
The result of paired t-test (two-tail) with multiple comparison correction indicated that
3-hydroxybutyrate (3-HB) and urea were significantly different after infection in infected
group (q< 0.001 and q< 0.001 respectively) and remained constant in the healthy control
group (Fig 3). 3-HB was altered after the infection with 22-fold decrease, whilst urea was ele-
vated with a fold-change of 1.42 (Table 3)
Plasma 3-hydroxybutyrate and infection
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ROC curve analysis: Urea and 3-HB then underwent a receiver operating characteristic
(ROC) analysis. Creatinine, the indicator for kidney failure, was also fitted in the analysis to
provide a reference. The area under curve (AUC) for 3-HB and urea were 0.97 (95% CI: 0.93–
1.00, accuracy = 0.91, sensitivity = 0.92, specificity = 0.91) and 0.85 (95% CI: 0.73–0.96, accu-
racy = 0.81, sensitivity = 0.72, specificity = 0.91), respectively. The combination of 3-HB and
urea produced an AUC of 0.98, but the sensitivity decreased. Therefore, data for 3-HB only
were included for further analysis. For comparison, the AUC for creatinine was 0.51 (accu-
racy = 0.54, sensitivity = 0.92, specificity = 0.13) (Fig 4).
Urine untargeted multivariate analysis
Infected group urine multivariate analysis. Similar data analysis approaches were
applied to urine GC-MS data between pre-infection (T1) and infection (T2) stages in infected
group. Five features were found to contribute most for group separation. After comparison
with the database, they were putatively identified as pyroglutamate, meso-Erythritol and L-
(-)-Arabitol, deoxyglucose and D-(+)-Talose.
Univariate analysis of selected features. Metabolite semi-quantification: The peak areas
of these metabolites were measured in the raw data (normalized to internal standard) for uni-
variate analysis. The result of paired t-test (two-tail) with multiple comparison correction dem-
onstrated that among them pyroglutamate, meso-Erythritol and L-(-)-Arabitol were elevated
greatly after infected with E.coli in infected group (q< 0.01) and did not change in the healthy
control group (Fig 5). Table 4 presented a summary of semi-quantification data of these
metabolites.
Fig 2. Plasma multivariate analysis showing changes of metabolic fingerprints between pre-infection (T1) and infection (T2) stages in
infected group (n = 36 in total). A. OPLS-DA score plot between T1 and T2 with R2Y = 0.868, Q2 = 0.669 and cross-validated p-value = 6.09×10−7.
R2Y showed that 86.8% of group variance was interpreted and Q2 represented for the prediction ability of this model with 66.9%. B. S-plot between T1
and T2. Each spot represents for a fragmentation ion.
https://doi.org/10.1371/journal.pone.0186497.g002
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ROC curve analysis: The predictive abilities of the three metabolites were evaluated by
ROC curve as well. All of them gave an area under the curve below 0.80, which was below the
desired threshold [36]. When combined these three metabolites, the AUC rose to 0.83 (95%
CI: 0.68–0.92) with increased specificity, but no improvement on sensitivity (results shown in
S2 Fig).
Levels of 3-hydroxybutyrate from T1 to T3
Plasma levels of 3-hydroxybutyrate. The level of 3-HB in plasma from T1 to T3 was mea-
sured. A line graph based on time points was drawn from its semi-quantification data to depict
changes at three time points (Fig 6A). The quantity of 3-HB first decreased with infection in all
the infected groups while it did not decrease in the control group. With treatments, the level of
3-HB increased after ciprofloxacin or Relinqing1 administration (p< 0.05 for both CPF and
Fig 3. Bean-plots show levels of plasma 3-hydroxybutyric acid and urea at pre-infection (T1) and infection (T2) stages (*** is q < 0.001, q
value is p value adjusted by Benjamini and Hochberg correction, n.s.: Not significant). A. Comparison of plasma 3-HB in infected group and
healthy control group between T1 and T2 (total n = 36 in infected group, paired t-test, two-tail; total n = 12 in healthy control group, Wilcoxon signed
rank test). B. Comparison of plasma urea in infected group and healthy control group between T1 and T2 (total n = 36 in infected group, paired t-
test, two-tail; total n = 12 in healthy control group, Wilcoxon signed rank test).
https://doi.org/10.1371/journal.pone.0186497.g003
Table 3. Summary of semi-quantification data for the selected plasma metabolites in the infected group between T1 and T2.
Metabolite Fold Change a p-value b q-value c
3-hydroxybutyrate -22.0 6.09×10−10 2.44×10−9
urea 1.4 2.5×10−5 5×10−5
lactate 1.1 6.5×10−2 6.5×10−2
cholesterol 1.2 5.7×10−2 6.5×10−2
a The trend of metabolite change was reported as upward (positive value) or downward (negative value)
b p value was calculated from paired t-test.
c q value is p value adjusted by Benjamini and Hochberg correction
https://doi.org/10.1371/journal.pone.0186497.t003
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RLQ groups). Table 5 shows the comparison between different groups at different time points.
Spearman correlation showed that 3-HB level in plasma strongly correlated with bacterial
number, r = -0.754, p value < 0.0001 (for RLQ and CPF treatments it was -0.76 and -0.72
respectively).
Urine levels of 3-hydroxybutyrate. The concentration of urine 3-HB also decreased
greatly at infection stage in the infected group. In the healthy control group, mice at T1 and T2
showed a similar level of 3-HB (Fig 6C). A line graph based on time points was also depicted
in the infected group showing the trend of 3-hydroxybutyrate under different physiological
statuses (Fig 6B). Urinary profile also exhibited a lower level of 3-hydroxybutyrate at infection
stage (T2) which corroborated the findings of the plasma analysis. In T3 the levels remained
depleted in urine, showing that this metabolite was not increased after treatment as it did in
plasma during recovery.
Fig 4. Receiver operating characteristic (ROC) curve prediction ability of UTI based on plasma 3-hydroxybutyrate,
urea, creatinine and the combination of 3-hydroxybutyrate and urea. CI: confidence interval.
https://doi.org/10.1371/journal.pone.0186497.g004
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Fig 5. Bean-plots show levels of urine pyroglutamate, meso-Erythritol and L-(-)-Arabitol at pre-infection (T1) and infection (T2) stages
(*** is q < 0.001, q value is p value adjusted by Benjamini and Hochberg correction, n.s.: Not significant). Total n = 36 in infected group,
paired t-test, two-tail; total n = 12 in healthy control group, Wilcoxon signed rank test.
https://doi.org/10.1371/journal.pone.0186497.g005
Table 4. Summary of semi-quantification data for the selected urine metabolites in infected group between T1 and T2.
Metabolite Fold Change a p-value b q-value c
Pyroglutamate 2.0 6.67×10−7 1.11×10−6
meso-Erythritol 3.7 1.47×10−10 7.35×10−10
L-(-)-Arabitol 3.5 3.06×10−8 7.65×10−8
Deoxyglucose -1.1 7.02×10−2 7.02×10−2
D-(+)-Talose -1.1 6.51×10−2 8.13×10−2
a The trend of metabolite change was reported as upward (positive value) or downward (negative value)
b p value was calculated from paired t-test.
c q value is p value adjusted by Benjamini and Hochberg correction
https://doi.org/10.1371/journal.pone.0186497.t004
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Levels of three urine metabolites during T1 to T3
Plasma levels of three urine metabolites. L-(-)-Arabitol and meso-Erythritol were not
detectable in plasma, while the amount of pyroglutamate showed no significant difference
between pre- and post-infection (data not shown).
Urine levels of three urine metabolites. The levels of urine pyroglutamate, meso-Erythri-
tol and L-(-)-Arabitol from pre-infection (T1) to post-treatment (T3) were also measured to
investigate any potential of reflecting the infection recovery process. These metabolites, instead
of following a clear pattern like plasma 3-hydroxybutyrate, showed changes that were not sig-
nificant overall. Results are shown in S3 Fig.
The aforementioned findings suggested that 3-hydroxybutyrate might be a candidate
metabolite for UTI detection and its management. A pure reference standard of 3-hydroxybu-
tyrate was analysed to confirm the identity of 3-hydroxybutyrate in the samples (S4 Fig).
Fig 6. Plasma and urine levels of 3-hydroxybutyrate (* q < 0.05, ** q < 0.01, *** q < 0.001, n.s.: Not significant). A. The change of plasma 3-HB
quantity in different groups at different time points (n = 6 per group at each time point). Comparison was made at post-treatment stage (T3) B. The
change of urine 3-HB quantity in different groups at different time points (n = 6 per group at each time point). C. Comparison of urinary 3-HB in infected
group and healthy control group between T1 and T2 (total n = 36 in infected group, paired t-test, two-tail; total n = 12 in control group, Wilcoxon signed
rank test). Results are presented as mean±S.D.
https://doi.org/10.1371/journal.pone.0186497.g006
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Discussion
In our study, we investigated the mouse metabolic response to urinary tract infection with
GC-MS-based metabolomics. A significant correlation between 3-HB in plasma and urinary
bacterial number/UTI was observed, showing a 22-fold reduction of 3-HB levels in the plasma
of E.coli-infected mice. For the UTI model study, the inoculation concentration and volume
were investigated. Plasma culture was used to assess if there was dissemination of bacteria into
the blood during infection and plasma creatinine was measured to evaluate kidney function.
Before infection, urine samples were collected and cultured to examine if the mice urine was
normal. At T1 (healthy) stage no bacterial colony was observed in the culture medium which
demonstrated that the urine samples were not contaminated and all the mice were free from
bacteria before infection.
3-HB association with infection in plasma
To provide an estimate of the prediction ability of selected metabolites, ROC analysis was per-
formed. In ROC curve analysis, sensitivity estimates how good the test is in identifying a dis-
ease while specificity evaluates how likely a subject without disease can be ruled out by the
test. AUC gives the overall accuracy of the test and can be used to compare different test
Table 5. Comparison of 3-HB levels in all groups at different time points in plasma and urine.
Plasma Time Point Comparison Mean (SD) a Mean (SD) p-Value b
Time Point 1
(pre-infection)
UTI vs CTR UTI = 0.35 (0.17) CTR = 0.47 (0.25) 0.69
RLQ vs CTR RLQ = 0.32 (0.23) CTR = 0.47 (0.25) 0.78
CPF vs CTR CPF = 0.40 (0.13) CTR = 0.47 (0.25) 0.31
Time Point 2
(infection)
UTI vs CTR UTI = 0.023 (0.0096) CTR = 0.35 (0.21) 0.004
RLQ vs CTR RLQ = 0.028 (0.0080) CTR = 0.35 (0.21) 0.009
CPF vs CTR CPF = 0.032 (0.024) CTR = 0.35 (0.21) 0.010
Time Point 3
(post-infection)
CTR vs UTI CTR = 0.42 (0.23) UTI = 0.030 (0.014) 0.008
RLQ vs UTI RLQ = 0.18 (0.069) UTI = 0.030 (0.014) 0.026
CPF vs UTI CPF = 0.21 (0.056) UTI = 0.030 (0.014) 0.026
Urine Time Point Comparison Mean (SD) Mean (SD) p-Value
Time Point 1
(pre-infection)
UTI vs CTR UTI = 0.57 (0.34) CTR = 0.62 (0.31) 0.19
RLQ vs CTR RLQ = 0.49 (0.41) CTR = 0.62 (0.31) 0.76
CPF vs CTR CPF = 0.71 (0.39) CTR = 0.62 (0.31) 0.47
Time Point 2
(infection)
UTI vs CTR URI = 0.017 (0.023)
(n = 4) c
CTR = 0.31 (0.28)
(n = 5)
0.016
RLQ vs CTR RLQ = 0.0097 (0.008)
(n = 3)
CTR = 0.31 (0.28)
(n = 5)
0.036
CPF vs CTR CPF = 0.014 (0.029) (n = 3) CTR = 0.31 (0.28)
(n = 5)
0.036
Time Point 3
(post-infection)
CTR vs UTI CTR = 0.44 (0.20)
(n = 5)
UTI = 0.019 (0.027)
(n = 3)
0.036
RLQ vs UTI RLQ = 0.037 (0.049)
(n = 5)
UTI = 0.019 (0.027)
(n = 3)
0.38
CPF vs UTI CPF = 0.10 (0.14)
(n = 4)
UTI = 0.019 (0.027)
(n = 3)
0.17
a Semi-quantification data obtained by the peak area of 3-HB divided by the peak area of internal standard
b p-value obtained from Mann-Whitney test
c number of mice showing the presence of features
SD: standard deviation
https://doi.org/10.1371/journal.pone.0186497.t005
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performances [37]. In plasma, urea as a single measure, 3-HB and 3-HB & urea together pro-
vided very high specificity. However, 3-HB generated higher sensitivity of 0.92 to identify mice
with UTI compared with urea 0.72 and 3-hydroxybutyrate & urea 0.87.
Urine pyroglutamate, meso-Erythritol and L-(-)-Arabitol combined returned an AUC of
0.83. This suggested a predictive potential of more than 80%, however the sensitivity was only
0.75 and their metabolic variation did not correlate with the recovery process.
After treatment (T3), the levels of 3-HB rebounded in plasma in both CPF and RLQ groups
while 3-HB remained unchanged in the UTI group. However, in urine, the level of 3HB didn’t
go back. It is because the excretion of 3HB involves renal ultrafiltration, reabsorption and
secretion. All of these could make the urine profile show a slower recovery process. By includ-
ing two different treatments in this experiment, we wanted to increase the reliability of any
UTI-related metabolites in plasma. The first treatment, ciprofloxacin, kills bacteria by inhibit-
ing its DNA gyrase [38] and the second, Relinqing1 granules, the exact mechanism of action
is still unknown. The level of 3-HB increased after the two different treatments, indicating that
3-hydroxybutyrate should be related to infection and the recovery. We observed a slower bac-
teriostatic effect with the RLQ treatment compared with CPF during the three-day period.
This was reflected in both the urine bacterial number and plasma 3-HB levels. The correlation
of 3-HB to bacterial number in RLQ and CPF treatments was -0.76 and -0.72 respectively.
Depletion of 3-hydroxybutyrate
This small acid 3-hydroxybutyrate is one of three ketone bodies together with acetoacetate and
acetone. Ketone bodies are generated from β-oxidation of free fatty acids in liver mitochondria
(S5 Fig) with three highly regulated enzymatic steps and are the main energy source for tissues
when glucose supply is limited [39, 40]. In human, the enzymes involved are different from
that in the mouse model, instead of long chain acyl-CoA dehydrogenase (LCAD) playing an
essential role in fatty acids oxidation, human mainly rely on very long chain acyl-CoA dehy-
drogenase (VLCAD) in fatty acids oxidation [41].3-HB decrease with UTI could be related to
the suppressed transport of plasma free fatty acid into the liver mitochondria. This mechanism
could be initiated by lipopolysaccharide (LPS) which is able to inhibit the enzymes that play a
role in the transport of fatty acids.
Lipopolysaccharide, a major component of the outer membrane of E.coli, is a toxin that is
released by E.coli. It can induce the secretion of pro-inflammatory cytokines [42]. LPS and
cytokines can enhance the expression of CD36/fatty acid translocase (FAT) which facilitates
the transfer of free fatty acids to the cytosol for re-esterification. They can also reduce the
expression of fatty acid-transport proteins (FATP) in the liver, the function of which is to
direct free fatty acid to mitochondria for ketogenesis [43, 44]. The increase in CD36/FAT and
decrease in FATP result in a lower pool of free fatty acid in the mitochondria, and in turn lead
to reduced levels of 3-HB as observed in our data.
Moreover, the inner mitochondrial membrane is impermeable for fatty acyl-CoA, it
demands a special carrier system to transfer fatty acyl-CoA to the mitochondrial matrix shown
in Fig 7A and 7B [45]. In this special carrier system, carnitine acyltransferase I (CAT-I) and
carnitine acyltransferase II (CAT- II) are two enzymes that play an important role. LPS has
also been reported to suppress the activity of CAT-I and CAT-II [44, 46]. In addition, Neufeld
et al. and Wannemacher et al. observed a decreased concentration of free fatty acid in plasma
during infection [47–49].
Plasma metabolic phenotyping is regarded as a collective "snapshot" of changes within the
body’s metabolism, thus the alteration of plasma metabolites could serve as good indicators of
health or disease status [50]. The result presented herein is based on a UTI mouse model, next
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Fig 7. Metabolic pathway of 3-hydroxybutyric acid. A. Transport of fatty acid in control mice B. Hypothesis
showing impaired transport of fatty acid in the infected mice.
https://doi.org/10.1371/journal.pone.0186497.g007
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steps will focus on other bacterial strains as the specificity of 3-HB is not yet proven in these
groups.
Conclusion
Our results indicated that 3-HB in plasma highly correlated to urinary tract infection with a
specificity of 0.91 and sensitivity of 0.92. It showed a significant decrease in the E.coli-infected
group and ROC curve revealed that 3-HB had a prediction ability of 0.97 (95% CI: 0.93–1.00).
A targeted longitudinal study of plasma 3-HB was also monitored which revealed that 3-HB
was able correlate with the recovery process. In addition, the reduced 3-HB was strongly asso-
ciated with urine bacterial number (r = -0.754, p< 0.0001). Further investigations will focus
on other bacterial strains in UTI.
Supporting information
S1 Fig. Data treatment workflow illustrates the overall design from untargeted multivari-
ate analysis to semi-targeted univariate analysis and further confirmation study. UTI: mice
treated with saline; CPF: mice treated with ciprofloxacin; RLQ: mice treated with Relinqing1
granules.
(TIF)
S2 Fig. Receiver operating characteristic (ROC) curve prediction ability of UTI based on
urine pyroglutamate, meso-Erythritol and L-(-)-Arabitol.
(TIF)
S3 Fig. Urine-targeted analysis of pyroglutamate, meso-Erythritol and L-(-)-Arabitol. A. The
change of urine pyroglutamate concentration in different groups at different time points (n = 6
per group at each time point). B. The change of urine meso-Erythritol in different groups at dif-
ferent time points (n = 6 per group at each time point). C. The change of urine L-(-)-Arabitol
concentration in different groups at different time points (n = 6 per group at each time point).
(TIF)
S4 Fig. A. Chromatogram and mass spectrum of 3-hydroxybutyrate reference standard. B.
Chromatogram and mass spectrum of 3-hydroxybutyrate from a plasma sample.
(TIF)
S5 Fig. β-oxidation of free fatty acids to 3HB. The enzyme highlighted in yellow is expressed
differently in mouse and human.
(TIF)
S1 Table. Bacterial number in mice urine at different inoculation concentrations.
(DOCX)
S2 Table. Bacterial number in mice urine at different inoculation volumes.
(DOCX)
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